Abstract Background Oral factor Xa inhibitors (FXaI) can be administered in fixed doses
without the need for routine laboratory monitoring. Anti-Xa assays can estimate …

Background Point-of-care testing (POCT) is regularly used to assess haemostasis in various
clinical settings. The impact of rivaroxaban on those POCT is still elusive. We aimed to study …

The direct acting oral anticoagulants (DOAC s), including dabigatran, rivaroxaban,
apixaban, and edoxaban, have favorable pharmacokinetic and pharmacodynamic …

Rivaroxaban and other oral direct factor Xa inhibitors (ODiXa) are currently developed for
prophylaxis and treatment of thromboembolic diseases using fixed doses. Although routine …

BACKGROUND Laboratory tests to assess novel oral anticoagulants (NOACs) are under
evaluation. Routine monitoring is unnecessary, but under special circumstances bioactivity …

Direct oral anticoagulants (DOACs) are increasingly used in the treatment and prophylaxis
of thromboembolism because of several advantages over vitamin K antagonists, including …

Global coagulation assays display variable effects at different concentrations of rivaroxaban.
The aim of this study is to quantify the ex vivo effects of low-dose rivaroxaban on …

INTRODUCTION: Rivaroxaban does not require monitoring nor frequent dose adjustment.
However, searching for the optimal dose in the individual patient may be useful in some …

Background: Determination of plasma rivaroxaban concentration may be necessary in
certain clinical situations. Rivaroxaban concentration can be accurately and rapidly …

Background: Direct oral factor Xa (FXa) inhibitors interfere with lupus anticoagulant (LA)
assays challenging antiphospholipid syndrome diagnosis in treated patients. We evaluated …